Media365
In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan.
Shares rose 3.2 per cent to HK$41.32 at the noon trading break, extending their year-to-date gain to 31.4 per cent.
WuXi Biologics credited the performance to its “follow and win the molecule” strategy, which aims to secure work across the full life cycle of client drugs – from early research to late-stage development and commercial production – supported by its technology platforms and execution track record.
The model allows the group to partner with both emerging biotech firms and multinational drug makers, tracking client molecules through development while capturing late-stage and commercial manufacturing projects.
The company, headquartered in Wuxi, in Jiangsu province, eastern China, added 209 new integrated projects in 2025.
Among them were 23 under its “win the molecule” strategy, including six in Phase III trials and commercial production, bringing the total to 945, CEO Chris Chen said at the JPMorgan Healthcare Conference in San Francisco last month.
